The Funding Committee is comprised of thirteen (13) members, except for the commissioner who shall serve as an ex officio member. Six (6) members shall be appointed by the governor, two (2) shall be appointed on the nomination of the temporary president of the senate, two (2) shall be appointed on the nomination of the speaker of the assembly, one (1) shall be appointed on the nomination of the senate minority leader and one (1) shall be appointed on the nomination of the assembly minority leader. A member of the funding committee shall also serve on the ethics committee.

13 Members

James V. McDonald M.D., M.P.H.(link is external)_[1], Commissioner, New York State Department of Health
 
Bradford C. Berk, M.D., Ph.D., is the Senior Vice President for Health Sciences at the University of Rochester and CEO of the Medical Center and Strong Health. Dr. Berk received his medical and doctoral degrees from the University of Rochester. He has served on the faculties of Harvard Medical School, Emory University, and the University of Washington. He previously was Chairman of Medicine (1999-2006) and Chief of the Cardiology Unit (1998-2003) at the University of Rochester. In addition, he was Director of the AB Cardiovascular Research Institute. Dr. Berk is a fellow of the American Heart Association and the American College of Cardiology, and a member of the Association of American Physicians. Dr. Berk is past-president of the North American Vascular Biology Organization (NAVBO). He is Consulting Editor for Circulation and Circulation Research and is on the editorial boards of ATVB and the Journal of Clinical Investigation. He serves on the National Heart, Lung and Blood Institute (NHLBI), Stem Cell Clinical Trial Network and Gene and Cell-Based Therapies Data and Safety Monitoring Board (DSMB). Dr. Berk has published more than 250 articles, chapters and books. His research interests include: molecular biology of renin-angiotensin-aldosterone system; regulation of endothelial cell function especially by shear stress; the role of oxidative stress in vascular injury biology and the genetic mechanisms of vascular remodeling.
 
Robin Anthony Elliott, M.A., has been Executive Director of the Parkinson’s Disease Foundation, Inc. since October, 1996. He has been active in development, communications and not-for-profit management in New York City for more than 35 years, serving as Vice President for Development and External Affairs at Teachers College, Columbia University (1988-95) and at Hunter College, The City University of New York (1982-88); as Deputy to the Chancellor for University Relations at the City University of New York (1979-82); and as Director of Information and Education for Planned Parenthood Federation of America (1971-79). Mr. Elliott grew up in southern England and received his B.A. from Magdalen College, Oxford University and his M.A. in American Government and Politics from Columbia University. Avocationally, he is active in reproductive health and rights, including as Member of the Board of Directors of Advocates for Youth, a Washington-based organization he co-founded in 1980, and has served on the vestry of St. Michael’s Church on West 99th Street and the boards of directors of the St. Cecilia Chorus and Community Health Charities. Until recently, he was Chair of New Yorkers for the Advancement of Medical Research, a pro-stem cell research coalition of disease advocacy groups, scientists and universities and citizens’ groups.
 
David C. Hohn, M.D., is President Emeritus and Executive Director of Health Policy at Roswell Park Cancer Institute (RPCI), where he served for 10 years as President and CEO. Dr. Hohn continues his national leadership role in health policy issues, especially as they relate to cancer research and treatment and training the next generation of cancer specialists. During his tenure as RPCI President, Dr. Hohn was widely credited with re-establishing the Institute as a leader in the national cancer community. He implemented the Institute’s first strategic plan focused on making RPCI internationally and nationally competitive in cancer science; led the restructuring of RPCI as a public benefit corporation; stabilized funding and increased revenue; recruited over 160 senior leadership faculty, top-tier clinicians and scientists; completed the $250 million renovation and rebuilding of the Institute campus; and implemented an innovative managed care strategy which opened regional access to RPCI. As Principal Investigator of the National Cancer Institute Cancer’s Center Support Grant, Dr. Hohn led the successful renewal of Roswell Park’s designation as a comprehensive cancer center – a designation the Institute has held continuously since 1974. Dr. Hohn came to RPCI from the University of Texas M.D. Anderson Cancer Center where, as Vice President for Patient Care from 1993 to 1997, his responsibilities included oversight of all clinical departments, clinical research programs and the protocol office.
 
David P. Speach, M.D., is an Associate Professor in the Departments of Orthopaedics and Rehabilitation and Physical Medicine and Rehabilitation (PMR) at the University of Rochester School of Medicine and Dentistry in Rochester, New York. He obtained his B.S. in Preprofessional studies from the University of Notre Dame in 1984 and his medical degree from SUNY Upstate Medical Center in 1988. After completing a transitional year internship in Internal Medicine in 1989, Dr. Speach served as a general medical officer with the United States Army 10th Mountain Division at Fort Drum, New York until 1993. He completed his residency in PMR at the University of Rochester in 1996 and has served on the faculty as a full time clinician teacher. The specialty of PMR was created to help individuals with impairment and disability to function to the fullest possible extent. Dr. Speach obtained subspecialty certification in Neuromuscular Medicine in 2009. His expertise is in the evaluation and treatment of pain, spinal disorders and the assessment of peripheral nerve disorders using electrodiagnosis.

The members serve without compensation but are allowed the necessary and actual expenses incurred in the performance of their duties. Estimated expenses below are based on travel expenses between the member's home and the Empire State Plaza or Metropolitan Area Regional Office where board meetings are held.

Costs FY 2020-21: $0
Costs FY 2021-22: $0
Costs FY 2022-23 $0
Est. Costs FY 2023-24: $0

The Board has no plans to meet further and is repealed as of 2025; accordingly, there are no plans to fill vacancies should they occur.